NLRP3 and inflammatory bowel disease: Second, since the NLRP3 inflammasome is associated with inflammatory bowel disease [47], NLRP3 inflammasome inhibition by ezetimibe treatment could attenuate inflammation in the gut, stabilising the gut microbiome that helps absorb choline.